CONVATEC GROUP PLC-UNSP ADR Business Summary

Convatec Group PLC (CNVVY) is a global medical products and technologies company that generates revenue primarily through the manufacture and sale of specialized devices for chronic condition management. The company operates across four primary business segments: Advanced Wound Care, providing high-performance dressings for acute and chronic wounds; Ostomy Care, offering stoma management solutions; Continence Care, supplying catheterization products; and Infusion Care, which produces infusion sets for insulin pumps and continuous drug delivery. Currently executing its "Accelerate" strategy, the firm is transitioning toward a high-margin, innovation-led model focused on the home-care and acute-care settings. Convatec maintains a leading position in the global chronic care market, competing directly with major players such as Coloplast, Smith & Nephew, and Mölnlycke Health Care, while distinguishing itself through a robust R&D pipeline and a significant market share in the United States. Originally established as a division of Bristol-Myers Squibb before its 2008 divestiture, the company is led by CEO Jonny Mason, a former engineer and accountant who previously served as the group’s CFO and held senior leadership roles at Currys PLC and Halfords. The executive leadership team includes CFO Fiona Ryder, who is currently managing a planned transition following a July 2026 announcement of her intent to step down, and Chief Operations Officer Peter Jarvis, who joined in April 2026 with extensive experience in global manufacturing. Dr. Divakar Ramakrishnan serves as the Chief Science, Innovation & Quality Officer, overseeing the company's technological advancements. The Board of Directors is chaired by Dr. John McAdam and recently added Tobias Hestler, the former CFO of Haleon, as a non-executive director. Major institutional backing is provided by investors such as Black Creek Investment Management and Fidelity International, reflecting confidence in the company’s strategic pivot toward high-growth medical specialties.